The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still no ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

Dec 23 (Reuters) - The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' (HIK.L), opens new tab generic version of Novo Nordisk's diabetes drug (NOVOb.CO), opens new tab ...

In 2015, it agreed a $390 million payment to settle allegations of kickbacks involving prescribing of its immunosuppressant drug Myfortic (mycophenolate mofetil) and thalassaemia treatment Exjade ...